Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is set to release its earnings data before the market opens on Thursday, November 2nd. Analysts expect Regeneron Pharmaceuticals to post earnings of $3.83 per share for the quarter.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s revenue was up 21.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $14.94 EPS for the current fiscal year and $16.37 EPS for the next fiscal year.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at 421.93 on Thursday. The stock’s 50 day moving average price is $446.40 and its 200-day moving average price is $458.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The firm has a market cap of $44.74 billion, a price-to-earnings ratio of 42.33 and a beta of 1.62.

REGN has been the topic of several research analyst reports. Leerink Swann restated a “positive” rating and set a $552.00 target price (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 1st. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Guggenheim reaffirmed a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $500.00 price target (up from $471.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Four research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $489.73.

TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/26/regeneron-pharmaceuticals-inc-regn-to-release-earnings-on-thursday.html.

In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 15,191 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $470.15, for a total transaction of $7,142,048.65. Following the completion of the transaction, the chairman now directly owns 329,543 shares of the company’s stock, valued at $154,934,641.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,468 shares of company stock valued at $42,312,448. 10.80% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.